$2.2BStrategic acquisitionHealthcare & Life Sciences
J&J to buy eye-disease biotech Ollin for $2.2B upfront
Johnson & Johnson has agreed to acquire Ollin Biosciences, a privately held, Austin-based clinical-stage company developing therapies for serious eye diseases, for $2.2 billion upfront. Up to about $1.1 billion more could follow in regulatory and commercial milestone payments. J&J will also sign a separate development funding agreement with Blackstone Life Sciences.
Why it matters: The deal gives J&J a late-stage bispecific antibody in ophthalmology that it says has best-in-class potential.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.
Following healthcare M&A?
The next big healthcare deal will be in our email the morning after it's announced, with the rest of the day's biggest deals. Free, with no paywalled links.
See what you get →